Oncotarget

Clinical Research Papers:

Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis

Yong-Chao Qiao, Wei Ling, Yan-Hong Pan, Yin-Ling Chen, Dan Zhou, Yan-Mei Huang, Xiao-Xi Zhang and Hai-Lu Zhao _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:66504-66515. https://doi.org/10.18632/oncotarget.16008

Metrics: PDF 2039 views  |   HTML 2888 views  |   ?  


Abstract

Yong-Chao Qiao1,2, Wei Ling1, Yan-Hong Pan1, Yin-Ling Chen1, Dan Zhou1, Yan-Mei Huang1, Xiao-Xi Zhang1,3 and Hai-Lu Zhao1,2,3

1 Center of Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin, China

2 Department of Immunology, Xiangya School of Medicine, Central South University, Changsha, China

3 Department of Immunology, Faculty of Basic Medicine, Guilin Medical University, Guilin, China

Correspondence to:

Hai-Lu Zhao, email:

Keywords: tType 1 diabetes mellitus; pramlintide; postprandial glucose; adverse events; meta-analysis

Received: January 20, 2017 Accepted: March 02, 2017 Published: March 08, 2017

Abstract

Aims: We aim to assess the efficacy and safety of pramlintide plus insulin therapy in patients with type 1 diabetes.

Methods: We included clinical studies comparing pramlintide plus insulin to placebo plus insulin. Efficacy was reflected by glycemic control and reduction in body weight and insulin use. Safety concerns were hypoglycemia and other adverse events. Subgroup analysis was performed for different doses (30, 60, 90 µg/meal) and durations (≤4, 26, 29, >29 weeks) of the treatment.

Results: A total of 10 randomized placebo-controlled studies were included for this meta-analysis (pramlintide, n=1978; placebo, n=1319). Compared with controls, patients given pramlintide had significantly lower HbA1c (p < 0.001), total daily insulin dose (p = 0.024), mean mealtime insulin dose (p < 0.001), body weight (p < 0.001) and postprandial glucose level (p = 0.002). The addition of pramlintide increased the incidence of nausea (p < 0.001), vomiting (p < 0.001), anorexia (p < 0.001) and hypoglycemia (p < 0.05) at the initiation of the treatment. The efficacy and adverse reactions of pramlintide were largely significant for the different doses and durations of the treatment.

Conclusions: The addition of pramlintide to insulin therapy in patients with type 1 diabetes improves glycemic control and reduces insulin requirement and body weight while bringing transient hypoglycemia and digestive disorders.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16008